Physician profile
Nayan Gowda
NPI 1922294388
$3,179.10
in general payments reported to CMS, 2019-2025
13 companies · $58.53 in 2025
The $58.53 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $170 · 2021: $180 · 2022: $111 · 2023: $2,188 · 2024: $74.10 · 2025: $58.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,113 · Food and Beverage: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,112.50 |
| Food and Beverage | $208.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,112.50 | 2023 | Benlysta |
| Vifor Pharma, INC. | $261.24 | 2019-2025 | Veltassa |
| Amgen INC. | $206.16 | 2019-2024 | Aranesp, Tavneos, Parsabiv |
| Bard Peripheral Vascular, INC. | $135.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $134.00 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $100.40 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $52.70 | 2019-2025 | Farxiga |
| Nxstage Medical, INC. | $46.01 | 2022 | |
| Genzyme Corporation | $40.32 | 2019-2020 | |
| Horizon Therapeutics Plc | $35.39 | 2019-2020 | |
| Scpharmaceuticals INC. | $24.02 | 2023 | |
| Opko Pharmaceuticals, LLC | $17.39 | 2019 | |
| Ardelyx, INC. | $13.64 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayan Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.